BioInvent International AB (BINV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioInvent International AB (BINV) has a cash flow conversion efficiency ratio of 0.082x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr66.78 Million) by net assets (Skr810.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioInvent International AB - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how BioInvent International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioInvent International AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioInvent International AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinch AB (publ)
LSE:0RBI
|
0.012x |
|
ECB Bancorp Inc.
NASDAQ:ECBK
|
0.025x |
|
Gaon Group Ltd
TA:GAGR
|
0.026x |
|
Fountaine Pajo
PA:ALFPC
|
-0.038x |
|
Silver Mountain Resources Inc
V:AGMR
|
-0.044x |
|
Chongkundang
KO:001630
|
0.040x |
|
Sino-Ocean Group Holding Limited
F:3SD
|
0.107x |
|
Isu Chemical Co Ltd
KO:005950
|
0.147x |
Annual Cash Flow Conversion Efficiency for BioInvent International AB (2002–2024)
The table below shows the annual cash flow conversion efficiency of BioInvent International AB from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr885.82 Million | Skr-380.47 Million | -0.430x | -64.64% |
| 2023-12-31 | Skr1.31 Billion | Skr-341.69 Million | -0.261x | -916.36% |
| 2022-12-31 | Skr1.61 Billion | Skr-41.23 Million | -0.026x | +85.73% |
| 2021-12-31 | Skr1.37 Billion | Skr-245.84 Million | -0.180x | -113.52% |
| 2020-12-31 | Skr743.50 Million | Skr-62.62 Million | -0.084x | +88.62% |
| 2019-12-31 | Skr169.44 Million | Skr-125.43 Million | -0.740x | +54.13% |
| 2018-12-31 | Skr87.62 Million | Skr-141.39 Million | -1.614x | -176.96% |
| 2017-12-31 | Skr130.22 Million | Skr-75.88 Million | -0.583x | -86.35% |
| 2016-12-31 | Skr230.44 Million | Skr-72.05 Million | -0.313x | +87.31% |
| 2015-12-31 | Skr29.45 Million | Skr-72.57 Million | -2.464x | -69.91% |
| 2014-12-31 | Skr52.43 Million | Skr-76.03 Million | -1.450x | -30.04% |
| 2013-12-31 | Skr49.01 Million | Skr-54.65 Million | -1.115x | +68.83% |
| 2012-12-31 | Skr47.62 Million | Skr-170.38 Million | -3.578x | -790.00% |
| 2011-12-31 | Skr137.95 Million | Skr-55.45 Million | -0.402x | +74.66% |
| 2010-12-31 | Skr74.19 Million | Skr-117.70 Million | -1.586x | +30.58% |
| 2009-12-31 | Skr55.63 Million | Skr-127.14 Million | -2.285x | -1308.90% |
| 2008-12-31 | Skr231.30 Million | Skr43.73 Million | 0.189x | +220.57% |
| 2007-12-31 | Skr214.12 Million | Skr12.63 Million | 0.059x | +106.42% |
| 2006-12-31 | Skr110.15 Million | Skr-101.23 Million | -0.919x | -90.80% |
| 2005-12-31 | Skr219.00 Million | Skr-105.48 Million | -0.482x | -15.43% |
| 2004-12-31 | Skr212.68 Million | Skr-88.74 Million | -0.417x | -92.09% |
| 2003-12-31 | Skr304.96 Million | Skr-66.25 Million | -0.217x | -710.31% |
| 2002-12-31 | Skr394.25 Million | Skr-10.57 Million | -0.027x | -- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more